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The	objective	of	this	review	was	to	perform	a	literature	compilation	of	all	the	equine	
publications	 that	 used	 dexmedetomidine	 as	 the	 first	 article	 on	 this	 topic	was	 pub-
lished,	in	2005.	We	also	aimed	to	answer	the	question	whether	the	use	of	dexmedeto-
midine	can	currently	be	justified.	For	that,	we	compiled	information	from	databases,	
such	as	PubMed,	Google	Scholar	and	Web	of	Science	and	the	proceedings	of	the	last	
veterinary	 anaesthesiology	meetings.	Dexmedetomidine	 is	 an	 attractive	 drug	 to	 be	
used	in	horses,	mainly	due	to	its	pharmacokinetic	profile	and	pharmacodynamics	that	
favour	its	use	as	intravenous	constant	rate	infusion	(CRI).	Nowadays,	its	clinical	use	is	
popular	for	sedation	in	prolonged	standing	procedures	and	during	partial	intravenous	
anaesthesia	(PIVA)	and	total	intravenous	anaesthesia	(TIVA).	However,	legal	require-
ments	for	its	use	should	be	taken	into	account.
1  | INTRODUCTION
In	1999,	the	Food	and	Drug	Administration	(FDA)	of	the	United	States	
of	 America	 (USA)	 approved	 dexmedetomidine,	 the	 most	 selective	
α2-	agonist,	for	use	as	a	constant	rate	infusion	(CRI)	to	provide	seda-
tion	and	analgesia	 in	 intensive	care	units	 (ICU)	during	periods	of	up	
to	 1	day.	The	 drug	was	marketed	 as	 Precedex®	 (Hospira,	 Inc.,	 Lake	
Forest,	IL,	USA).	A	new	indication	was	approved	by	the	FDA	in	2008	
for	sedation	in	nonintubated	patients	before	and	during	surgical	and	
nonsurgical	procedures.	In	the	European	Union	(EU),	Dexdor®	(Orion	
Corporation,	Espoo,	Finland)	was	licenced	in	2011	for	use	as	CRI	for	
sedation	of	adult	ICU	patients.
In	veterinary	medicine,	the	European	Commission	granted	a	mar-
keting	 authorization	 for	 Dexdomitor®	 (Orion	 Corporation,	 Espoo,	
Finland)	 in	 2002	 and	 renewed	 in	 2007.	This	α2-	agonist	 is	 indicated	
for	use	as	a	sedative	and	analgesic	in	dogs	and	cats	to	facilitate	clin-
ical	 examinations,	 clinical	 procedures	 and	minor	 surgeries,	 and	 as	 a	
pre-	anaesthetic	to	general	anaesthesia.	It	is	the	active	enantiomer	of	
medetomidine	(Savola	&	Virtanen,	1991),	which	is	entirely	responsible	
for	 the	 sedative,	 analgesic	 and	 anaesthetic	 sparing	 effects	 (Ansah,	
Raekallio,	&	Vainio,	1998;	Kuusela	et	al.,	2000;	Segal,	Vickery,	Walton,	
Doze,	 &	Maze,	 1988).	 It	 is	 slightly	more	 potent	 than	 the	 racemate	
(Kuusela	et	al.,	2000;	Savola	&	Virtanen,	1991)	and	less	likely	to	cause	
drug	interactions	(Kharasch,	Herrmann,	&	Labroo,	1992).
In	equine	practice,	sedation	with	α2-	agonists,	alone	or	combined	
with	other	drugs,	is	the	cornerstone	for	standing	procedures	and	prior	
to	general	anaesthesia,	mainly	due	to	their	potent	sedative	and	good	
analgesic	properties.	Up	to	2005,	the	use	of	dexmedetomidine	had	not	
been	reported	in	the	equine.	Since	then,	several	experimental	and	clin-
ical	studies	have	been	published.	The	main	reason	for	this	increase	in	
publications	relies	on	its	beneficial	pharmacological	profile,	including	
a	short	half-	life	and	a	rapid	redistribution	(Bettschart-	Wolfensberger	
et	al.,	2005).	These	properties	make	this	drug	attractive,	favouring	its	
investigation	 as	 intravenous	 (i.v.)	 infusions	 in	 the	 currently	 popular	
areas	of	equine	standing	procedures	and	partial	(PIVA)	and	total	intra-
venous	anaesthesia	(TIVA).	However,	its	use	may	be	restricted	due	to	
current	legislation,	which	differs	between	countries	around	the	world	
(e.g.,	USA	vs.	EU).	In	most	European	countries,	off-	label	use	of	drugs	
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is	only	allowed	if	no	licensed	alternative	is	available,	and	only	to	avoid	
unacceptable	 suffering	of	 the	animal.	 In	addition,	 in	 food-	producing	
animals,	 off-	label	 use	 is	 only	 allowed	 for	 drugs	 that	 are	 included	 in	
Table	1	of	the	Annex	of	EU	Directive	37/2010.
2  | RESEARCH QUESTION
The	aim	of	the	present	review	was	to	perform	a	systematic	literature	
compilation	 including	all	 the	equine	studies	published	 from	2005	 in	
which	dexmedetomidine	was	used.	The	second	goal	was	 to	answer	
the	review	title,	which	questions	whether	the	use	of	dexmedetomi-
dine	in	horses	can	nowadays	be	justified,	taking	into	account	current	
legislation	restrictions.
3  | ARTICLE SELECTION
A	 literature	 search	 strategy	 included	 the	 search	 engines	 PubMed,	
Google	Scholar	and	Web	of	Science,	and	proceedings	of	the	last	vet-
erinary	 anaesthesiology	 meetings	 (up	 to	 2017).	 The	 keywords	 and	
terms	 entered	 were	 “dexmedetomidine	 horse.”	 “dexmedetomidine	
horses,”	“dexmedetomidine	donkey,”	“dexmedetomidine	pony,”	“dex-
medetomidine	ponies”	and	“dexmedetomidine	equine,”	each	of	these	
either	alone	or	in	combination	with	“partial	intravenous	anaesthesia,”	
“total	 intravenous	 anaesthesia,”	 “standing,”	 “pharmacokinetics”	 or	
“pharmacodynamics.”
The	 eligibility	 criteria	 included	 abstracts	 and	 studies	 (published	
or	 online	 articles	 and	 abstracts	 presented	 in	 congresses)	written	 in	
English,	experimental	or	clinical,	blinded	or	nonblinded,	reporting	the	
use	of	dexmedetomidine	 in	equine	 species	 for	 standing	 sedation	or	
during	general	anaesthesia	(PIVA	or	TIVA),	as	well	as	pharmacokinetic	
and	other	studies	or	case	reports.	All	the	identified	studies	were	eval-
uated	by	the	main	researcher	(MGM)	to	determine	their	suitability	for	
inclusion	and	screened	independently	by	the	other	three	independent	
reviewers	(FG,	SPL,	SS).	Furthermore,	all	the	publications	were	classi-
fied	according	to	the	levels	of	evidence	categorized	and	documented	
by	 the	 Oxford	 Centre	 for	 Evidence-	Based	 Medicine	 (Howick	 et	al.,	
2011;	Appendix	1).
A	 total	 of	 28	manuscripts	 published	 in	 English	 in	 peer-	refereed	
journals	or	abstracts	presented	in	the	proceedings	of	specialist	meet-
ings	were	reviewed.	Most	of	these	papers	described	the	use	of	dex-
medetomidine	 in	horses;	 four	enrolled	experimental	ponies	and	two	
studies	were	performed	in	donkeys.	The	subjects	of	the	different	stud-
ies	are	shown	in	Table	1	and	evaluated	in	Table	2.	Due	to	their	study	
design,	 some	 studies	 are	 included	 in	 different	 groups,	 for	 example,	
Duke-	Novakovski,	 Palacios-	Jimenez,	 Wetzel,	 Rymes,	 and	 Sanchez-	
Teran	(2015)	in	both	PIVA	and	TIVA	studies.
4  | REPORTED STUDIES (2005–2017)
4.1 | Studies in standing horses (9)
4.1.1 | Pharmacokinetic (PK) and pharmacodynamic 
studies (PD) (4)
Bettschart-	Wolfensberger	et	al.	 (2005)	 first	 studied	 the	PK	of	an	 i.v.	
3.5	μg/kg	bolus	in	14	ponies,	eight	mature	(4.4	±	1.1	years)	and	six	old	
adults	(20	±	3.2	years),	by	means	of	capillary	gas	chromatography	with	
negative	 ion	 chemical	 ionization	mass	 spectrometry.	 A	 noncompart-
mental	analysis	was	used,	and	PK	parameters	were	the	following:	peak	
concentration	4.60	±	2.86	and	3.77	±	1.52	ng/ml,	half-	life	19.80	±	9.63	
and	 28.96	±	7.61	min	 and	 area	 under	 plasma	 concentration–time	
curve	 34.55	±	11.37	 and	 44.28	±	22.66	ng	min	ml−1	 for	 mature	 and	
adults,	respectively.	Dexmedetomidine	plasma	levels	declined	rapidly	
in	both	groups	and	fell	beyond	limits	of	quantification	(LOQ)	(0.05	ng/
ml)	within	60–90	min.	With	regard	to	cardiopulmonary	effects,	Heart	
rate	 (HR)	was	not	different	 from	presedation	values,	whereas	stroke	
volume	 (SV)	 and	 cardiac	 index	 (CI)	 decreased	 significantly	 for	 5	 and	
10	min,	 respectively,	 with	 mean	 maximal	 decreases	 of	 34%	 for	 SV	
and	44%	for	CI.	Increases	in	systemic	vascular	resistance	index	(SVRI)	
(95%),	systolic	(SAP)	(7%),	mean	(MAP)	(8%),	diastolic	(DAP)	(19%)	and	
mean	pulmonary	(mPAP)	(11%)	arterial	pressures	occurred	for	5	min.	
Subsequent	reductions	 in	SAP,	MAP	and	DAP	occurred	between	20	
and	45	min	and	in	the	respiratory	frequency	(fR)	for	the	complete	dura-
tion	of	the	experiment	(60	min).	Cardiac	output	(CO)	was	obtained	by	
the	thermal	dilution	technique	to	calculate	CI	and	SVRI.
Rezende,	Grimsrud,	Stanley,	Steffey,	and	Mama	 (2015)	also	con-
sidered	 a	 noncompartmental	 analysis	 to	describe	 the	PK	of	 a	5	μg/
kg	i.v.	bolus,	by	means	of	liquid	chromatography–mass	spectrometry	
(LC-	MS).	 In	 this	 study	with	 eight	 adults,	 healthy	 horses,	 peak	 con-
centration	was	5.70	±	3.52	ng/ml,	with	a	rapid	decrease	 (elimination	
half-	life	was	8.03	±	0.84	min).	Volumes	of	distribution	and	total	body	
clearance	(CL)	showed	a	large	variation	between	individuals.	Times	of	
last	detection	varied	from	30	to	60	min	(LOQ	=	0.1	ng/ml),	with	one	
individual	exception,	up	to	360	min.	Heart	rate	decreased	significantly	
for	10	min	(maximal	mean	decrease	at	4	min	after	drug	administration	
of	35%),	with	an	“irregular	rhythm”	detected	in	four	of	the	horses	in	
that	period.	A	wide	variability	in	fR	was	observed	between	individuals,	
mostly	 reductions,	 but	 three	of	 them	 showed	 tachypnea	 and	one	 a	
TABLE  1 Numbers	of	articles	using	dexmedetomidine	in	horses	
and	donkeys	(2)
Type of study
Number 
of 
articles
PK/PD 4
Other	PD 5
PIVA 12
MACNM 2
TIVA 3
Other 2
Total 28
PK,	pharmacokinetics;	PD,	pharmacodynamics;	PIVA,	partial	 intravenous	
anaesthesia;	 MACNM,	 minimum	 alveolar	 concentration	 no	 movement;	
TIVA,	total	intravenous	anaesthesia.
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very	laboured	breathing	pattern	that	normalized	by	30	min.	Reduced	
gastrointestinal	motility	occurred	for	60	min	after	drug	administration.	
Statistically	 significant	 reductions	 in	 head	 height	 above	 the	 ground	
(HHAG)	were	observed	for	60	min,	with	a	mean	maximal	reduction	of	
70%	for	up	to	10	min,	being	lower	than	50%	from	baseline	values	for	
approximately	30	min.	Mechanical	nociceptive	thresholds	were	higher	
than	pretreatment	data	for	the	first	30	min.
Grimsrud	et	al.	(2015)	compared	the	PK	using	a	two-	compartment	
model	 by	 LC-	MS,	 with	 further	 PK/PD	 modelling	 of	 i.v.	 detomidine	
(30	μg/kg),	medetomidine	(10	μg/kg)	and	dexmedetomidine	(5	μg/kg),	
reporting	the	drug	concentration-	effect	data.	Dexmedetomidine	had	
the	highest	CL,	0.0441	(19)	L	min−1	kg−1	(estimate	[residual	standard	
error]),	approximately	twice	that	of	medetomidine	 (0.0210	[12])	and	
detomidine	was	the	lowest	(0.0132	[4]).	Volumes	of	distribution	(L/kg)	
for	 the	central	 (V1)	and	peripheral	 (V2)	compartments	were	approxi-
mately	twice	smaller	for	dexmedetomidine	than	medetomidine	(0.236	
[38]	vs.	0.474	[14]	for	V1	and	0.163	[38]	vs.	0.314	[11]	for	V2).	With	
regard	to	PD	parameters,	the	HR	decreased	by	31%	after	medetomi-
dine	and	dexmedetomidine,	whereas	with	detomidine,	it	was	reduced	
by	 approximately	 51%.	The	HHAG	 drug	 concentrations	 required	 to	
obtain	 inhibition	at	half-	maximal	effect	 (IC50)	were	10	 times	greater	
with	 detomidine	 than	 after	 medetomidine	 and	 dexmedetomidine.	
Comparing	medetomidine	and	dexmedetomidine,	the	latter	had	a	sig-
nificantly	lower	hyperglycaemic	effects.
Finally,	Ranheim,	Risberg,	Spadavecchia,	Landsem,	and	Haga	(2015)	
detected	substantial	 individual	differences	in	the	PK	and	PD	param-
eters	 after	 a	 150	min	 8	μg	kg−1	hr−1	 dexmedetomidine	CRI	 in	 seven	
healthy	horses.	Dexmedetomidine	was	detected	by	LC-	MS,	 and	 the	
parameters	were	 calculated	 using	 noncompartmental	methods.	 The	
harmonic	mean	(SD)	plasma	elimination	half-	life	(Lambda	z	half-	life)	for	
dexmedetomidine	was	20.9	 (5.1)	min,	CL	0.3	 (0.20)	L	min−1	kg−1 and 
volume	of	distribution	at	steady	state	13.7	(7.9)	L/kg.	With	regard	to	
sedation	levels,	HHAG	varied	together	with	dexmedetomidine	plasma	
concentrations.	After	the	CRI	was	discontinued,	all	horses	returned	to	
baseline	HHAG	values	within	65	min.
4.1.2 | Other PD studies in standing horses and 
donkeys (5)
In	an	experimental,	randomized,	cross-	over	study	involving	five	adult	
healthy	horses,	Müller,	Hopster,	Hopster-	Iversen,	Rohn,	and	Kästner	
(2012)	compared	the	sedative	and	antinociceptive	effects	of	a	dexme-
detomidine	protocol	consisting	of	a	bolus	of	3.5	μg/kg	followed	by	an	
infusion	of	5	or	7	μg	kg−1	hr−1,	with	a	xylazine	regime	(0.5	mg/kg	plus	
1	mg	kg−1	hr−1	CRI),	 for	 120	min.	 The	 lower	 dexmedetomidine	 infu-
sion	 rate	 (5	μg	kg−1	hr−1)	 produced	 less	 reduction	 in	HHAG,	 around	
30%–50%,	whereas	the	higher	(7	μg	kg−1	hr−1)	produced	similar	steady	
reductions	as	xylazine,	around	70%	for	the	duration	of	the	CRIs.	The	
higher	 rate	of	dexmedetomidine	was	calculated	based	on	the	 lower	
one,	by	adding	additional	boli	 to	reach	equivalent	 levels	of	sedation	
than	the	reached	by	the	xylazine	regime.	Significant	decreases	in	HR	
were	 observed	 during	 the	majority	 of	 the	 CRI,	 without	 differences	
between	treatments.	First-	and	second-	degree	atrioventricular	blocks	
(AVBs)	were	observed	 in	several	horses	after	 the	dexmedetomidine	
boli	and	during	the	infusions.	Decreases	in	fR	from	baseline	were	seen	
over	the	whole	period	only	in	those	horses	receiving	the	higher	rate	
of	dexmedetomidine.	Significant	 increases	 in	the	thermal	thresholds	
compared	 to	baseline	occurred	 from	15	min	after	bolus	administra-
tion	up	to	the	end	of	the	infusions.	The	higher	dexmedetomidine	rate	
prolonged	these	threshold	increases	for	more	30	min.	No	differences	
between	treatments	were	observed.
In	 another	 experimental	 randomized,	 cross-	over	 study	 with	 10	
adults,	 healthy	 horses,	 Risberg,	 Spadavecchia,	 Ranheim,	 Krontveit,	
and	Haga	(2014)	studied	the	sedative	and	antinociceptive	effects	of	
dexmedetomidine	CRIs	 at	 2,	 4	 and	 6	μg	kg−1	hr−1	 after	 an	 i.v.	 bolus	
0.96 μg/kg,	related	to	their	measured	plasma	concentrations.	Sedation	
was	assessed	with	a	visual	analogue	scale	(VAS),	presented	as	a	 line	
of	100	mm,	with	0	mm	representing	no	sedation,	and	100	mm	heavy	
sedation.	The	mean	sedation	VAS	scores	increased	dose-	dependently	
according	 to	 the	 rate	 infused	 and	were	 0	 (range	 0–10	mm),	 20	mm	
(range	0–46	mm)	and	58	mm	(range	11–85	mm),	for	the	rates	2,	4	and	
6 μg	kg−1	hr−1,	respectively,	with	large	variability	between	individuals.	
This	may	be	explained	by	the	large	individual	variations	in	plasma	con-
centrations	measured.	Sedation	 levels	gradually	 increased	over	 time	
during	the	infusion	and	up	to	30	min	postinfusion	in	the	6	μg	kg−1	hr−1 
infusion.	Antinociception	was	assessed	by	application	of	electrical	sin-
gle	and	repeated	stimulation.	Increased	electrical	thresholds	were	only	
observed	at	4	and	6	μg	kg−1	hr−1,	which	remained	for	at	least	30	min	
after	discontinuing	the	CRIs.
In	an	experimental,	blinded,	randomized,	cross-	over	study	involv-
ing	 six	 adults,	 healthy	 horses,	Medeiros	 et	al.	 (2017)	 compared	 the	
sedative	and	cardiopulmonary	effects	of	a	90-	min	dexmedetomidine	
i.v.	infusion	alone	(3.5	μg/kg,	followed	by	a	5	μg	kg−1	hr−1	CRI),	or	com-
bined	with	butorphanol	(20	μg/kg	plus	a	24	μg	kg−1	hr−1	CRI).	Maximal	
HHAG	reductions	 for	 the	 treatments	dexmedetomidine	alone	 (54%)	
or	combined	with	butorphanol	 (58%)	occurred	at	15	min	after	bolus	
administration	and	beginning	of	the	CRIs,	with	the	presence	of	ataxia.	
Afterwards,	 HHAG	 reduction	 values	 were	 never	 higher	 than	 50%,	
failing	 to	maintain	 a	 steady	 sedation.	With	 regard	 to	 the	 cardiopul-
monary	variables,	no	differences	were	observed	between	treatments.	
Significant	decreases	in	HR	occurred	for	90	and	30	min	compared	to	
baseline,	in	treatment	dexmedetomidine	alone,	and	the	combination,	
respectively.	Second-	degree	AV-	blocks	were	observed	in	both	groups	
for	the	first	15	min,	with	one	horse	for	up	to	60	min	in	the	combina-
tion	treatment.	Thermal	dilution	technique	was	used	for	measurement	
of	CO.	In	both	treatments,	CI	and	oxygen	delivery	index	(DO2I)	were	
similarly	reduced	for	the	first	30	min	(maximal	reductions	at	5	min	of	
41%	 and	 48%	 for	 CI	 and	DO2I,	 respectively),	while	 SVRI	 increased	
for	 15	min	 (maximal	 increases	 of	 65%	 at	 5	min).	 Values	 of	 fR were 
lower	for	the	whole	infusion	period	with	both	treatments	and	for	up	
to	30	min	after	the	end	of	the	CRI	when	only	dexmedetomidine	had	
been	infused.
In	 donkeys,	 the	 sedative	 and	 antinociceptive	 effects	 of	 differ-
ent	 i.v.	boli	 of	α2-	agonists	were	 reported	by	 Lizarraga	 and	Janovyak	
(2013)	 in	 an	 experimental,	 blinded,	 randomized,	 cross-	over	 study	
enrolling	six	adults,	healthy	animals,	using	mechanical	stimuli	for	the	
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antinociceptive	tests.	Dexmedetomidine	(3.5	μg/kg)	produced	similar	
antinociception	as	xylazine	(1.1	mg/kg),	detomidine	(20	μg/kg),	romi-
fidine	(100	μg/kg)	and	medetomidine	(5	μg/kg)	for	30	min.	However,	
from	30	to	60	min,	mechanical	thresholds	after	dexmedetomidine	and	
xylazine	were	significantly	 lower	than	those	achieved	by	detomidine	
or	 romifidine.	 Sedation	was	 15–25	min	 longer	 than	 antinociception	
with	all	 treatments.	A	 recent	 study	by	Lizarraga,	Castillo-	Alcala,	 and	
Robinson	 (2017)	 studied	 the	 sedative	 and	 antinociceptive	 (mechan-
ical)	dose-	dependent	properties	of	2,	3,	4	and	5	μg/kg	of	dexmede-
tomidine	 in	 an	 experimental,	 blinded,	 randomized,	 cross-	over	 study	
with	six	adults,	healthy	donkeys.	All	the	doses	produced	sedation	(last-
ing	up	to	60	min),	with	shorter-	lasting	 (40–55	min),	dose-	dependent	
antinociception.
4.2 | PIVA studies (12)
Based	 on	 Bettschart-	Wolfensberger	 et	al.	 (2005),	 Marcilla,	
Schauvliege,	 Duchateau,	 and	 Gasthuys	 (2010)	 designed	 an	 experi-
mental	study	with	six	adults,	healthy	ponies.	Each	pony	was	anaesthe-
tized	once	for	150	min,	with	periods	of	30	min	alternating	saline	with	
low	and	high	doses	of	dexmedetomidine.	After	an	i.v.	sedation	dose	
of	3.5	μg/kg,	rates	of	1	and	1.75	μg	kg−1	hr−1 produced minimal and 
comparable	cardiopulmonary	effects.	These	changes	included	minor,	
but	statistically	significant	decreases	in	HR,	CI,	arterial	(CaO2)	and	ve-
nous	(CvO2)	oxygen	content,	and	oxygen	delivery	(DO2)	and	increases	
in	 systemic	 vascular	 resistance	 (SVR),	 SAP	 and	 right	 atrial	 pressure	
(RAP).	No	periods	of	severe	bradycardia	or	AVBs	were	observed.	The	
authors	justified	the	safe	use	of	those	protocols	as	the	decreases	in	
CI	and	DO2	were	less	than	10%	of	the	baseline	values	and	are	usually	
well	tolerated	in	anaesthetized,	healthy	horses.
In	 a	 clinical,	 blinded,	 placebo-	controlled,	 randomized	 study	with	
40	 adults,	 healthy,	 client-	owned	 horses,	 undergoing	 surgical	 proce-
dures	 under	 general	 anaesthesia	 for	 more	 than	 60	min,	 the	 limited	
cardiopulmonary	 effects	 of	 the	 1.75	μg	kg−1	hr−1		 rate	 described	 in	
Marcilla	et	al.	 (2010)	were	confirmed	(Marcilla,	Schauvliege,	Segaert,	
Duchateau,	&	Gasthuys,	2012).	After	the	3.5	μg/kg	sedation	dose,	11	
horses	required	additional	doses	to	obtain	acceptable	sedation	before	
induction	of	general	anaesthesia.	During	anaesthesia,	only	two	of	40	
horses	 showed	 second-	degree	AVBs,	with	 “no	 need	 for	 treatment.”	
No	 reduction	 in	 the	 end-	tidal	 isoflurane	 concentration	 (FE′ISO)	was	
found	compared	to	a	placebo	treatment.	The	authors	attributed	this	
to	the	study	design	and	the	fact	that	the	anaesthetist,	unaware	of	the	
treatment,	evaluated	the	anaesthetic	depth	in	a	subjective	way.	After	
a	bolus	of	0.875	μg/kg,	better	recoveries	were	observed	in	the	dexme-
detomidine	treatment	compared	to	the	placebo	(Marcilla	et	al.,	2012).
In	 another	 clinical,	 blinded,	 randomized	 study	 involving	 20	
adults,	 healthy,	 client-	owned	 horses,	 the	 same	 protocol,	 3.5	μg/
kg	 sedation	dose	 followed	by	a	CRI	 at	1.75	μg	kg−1	hr−1,	 seemed	 to	
be	 more	 adequate	 than	 a	 morphine-	based	 technique	 (0.15	mg/kg	
added	 to	 the	 dexmedetomidine	 sedation	 dose,	 followed	 by	 a	 mor-
phine	 0.1	mg	kg−1	hr−1	 CRI)	 (Gozalo-	Marcilla,	 Steblaj,	 Schauvliege,	
Duchateau,	 &	 Gasthuys,	 2013),	 as	 it	 guaranteed	 a	more	 stable	 an-
aesthesia	with	 less	extra	doses	of	ketamine	and	reduced	the	FE′ISO	
based	on	an	objective	flow	chart,	adapted	from	Enderle,	Levionnois,	
Kuhn,	and	Schatzmann	(2008).	Better	recoveries	were	seen	in	horses	
receiving	 dexmedetomidine,	 with	 no	 postoperative	 complications	
compared	with	the	morphine	treatment,	where	one	of	the	10	horses	
developed	postoperative	colic	and	pulmonary	oedema	and	two	others	
box-	walking	(Gozalo-	Marcilla,	Steblaj	et	al.,	2013).	Overall,	the	cardio-
pulmonary	changes	in	the	dexmedetomidine	treatment	compared	to	
morphine	included	significant	increases	in	MAP	and	DAP	values	and	
decreases	in	CI	and	stroke	volume	index	(SVI),	always	within	clinically	
acceptable	levels.	For	the	measurement	of	CO,	the	authors	in	Marcilla	
et	al.	(2010,	2012)	and	Gozalo-	Marcilla,	Steblaj	et	al.	(2013)	employed	
the	lithium	dilution	technique	(LiDCO).
A	1.5	μg	kg−1	hr−1	CRI,	without	loading	dose	and	after	sedation	with	
xylazine	and	anaesthetic	maintenance	with	sevoflurane	and	remifen-
tanil,	was	successfully	used	in	a	10-	year-	old	horse	for	a	radical	man-
dibulectomy	which	lasted	for	13	hr	(Benmansour	&	Duke-	Novakovski,	
2013).	In	a	60-	min	experimental,	nonblinded,	randomized,	cross-	over,	
study	 involving	 six	 adults,	 healthy,	 isoflurane-	anaesthetized	 horses,	
no	 significant	 differences	 in	 cardiopulmonary	 effects	 and	 recov-
ery	qualities	were	detected	between	a	dexmedetomidine	CRI	 alone	
(loading	 dose	 0.25	μg/kg	 followed	 by	 a	 CRI	 of	 1	μg	kg−1	hr−1)	 and	
combined	 with	 morphine	 (0.15	mg/kg	 plus	 a	 0.1	mg	kg−1	hr−1	 infu-
sion)	or	remifentanil,	CRI	at	6	μg	kg−1	hr−1	(Benmansour	et	al.,	2014).	
No	excitement	or	colic	was	seen	in	the	recovery.	Blood	samples	were	
taken	in	the	remifentanil	treatment	to	measure	the	concentrations	of	
this	drug	 (Benmansour,	Billinsky,	Duke-	Novakovski,	&	Alcorn,	2016).	
In	 an	 experimental,	 nonblinded,	 randomized,	 cross-	over	 study	 with	
six	adults,	healthy	horses	undergoing	arthroscopy	for	periods	around	
60–90	min,	Duke-	Novakovski	et	al.	(2015)	compared	a	propofol-	based	
(8	mg	kg−1	hr−1)	TIVA	protocol	with	ketamine	(1	mg	kg−1	hr−1	CRI)	and	
dexmedetomidine	(1.5	μg	kg−1	hr−1)	 infusions	with	a	PIVA	technique,	
replacing	the	propofol	CRI	by	isoflurane.	The	horses	had	been	previ-
ously	sedated	with	i.v.	0.5	mg/kg	of	xylazine	for	instrumentation	and	
extra	 0.5	mg/kg	 before	 induction,	 which	 consisted	 in	 i.v.	 ketamine	
(2	mg/kg)	and	propofol	(0.4	mg/kg).	Mean	FE′ISO	in	the	PIVA	proto-
col	was	approximately	1%	(range,	0.5%–1.3%).	The	CO,	measured	by	
the	thermodilution,	was	significantly	reduced	for	10	min	after	induc-
tion	(15%),	only	with	the	PIVA	protocol.	Between	treatments,	arterial	
partial	pressure	of	oxygen	(PaO2)	was	significantly	higher	in	the	PIVA	
protocol	compared	to	TIVA,	for	the	study	period	(mean	PaO2	values	of	
380	and	255	mmHg	for	PIVA	and	TIVA	at	60	min,	respectively),	with	
the	use	of	comparable	inspired	concentration	of	oxygen	(FiO2)	values	
(mean	values	between	77%	and	94%).
An	 experimental,	 blinded,	 randomized,	 cross-	over	 study	 with	
eight	 adults,	 healthy,	 isoflurane-	anaesthetized	 horses	 by	 Risberg,	
Ranheim,	Krontveit,	 Lervik,	 and	Haga	 (2016)	 compared	 a	PIVA	pro-
tocol	 with	 dexmedetomidine	 (8	μg/kg	 for	 sedation	 followed	 by	 a	
1.75 μg	kg−1	hr−1	CRI)	versus	a	saline	treatment.	At	equivalent	depths	
of	anaesthesia	(FE′ISO	0.7%	±	0.2%	and	0.9%	±	0.2%,	for	the	dexme-
detomidine	and	saline,	respectively),	statistical	significant	decreases	in	
HR	(16%),	CI	(22%)	and	DO2I	 (24%)	and	significant	increases	in	SAP	
(18%),	MAP	(19%),	DAP	(18%)	and	oxygen	extraction	(OE)	(32%)	were	
present	 in	horses	 receiving	a	CRI	of	dexmedetomidine	compared	 to	
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those	 receiving	 saline.	 For	 CO	measurement,	 the	 LiDCO	 technique	
was	used.	To	maintain	MAP	above	60	mmHg,	eight	horses	in	the	con-
trol	and	one	horse	in	the	dexmedetomidine	treatment	received	dobu-
tamine.	Recovery	qualities,	measured	with	 a	VAS	 scale,	were	better	
in	group	dexmedetomidine,	with	less	attempts	to	stand.	All	horses	in	
the	dexmedetomidine	group	stood	up	at	the	first	attempt,	whereas	in	
the	control	group,	horses	made	a	median	of	three	attempts	to	stand	
(range	1–8).
Sacks,	 Ringer,	 Bischofberger,	 Berchtold,	 and	 Bettschart-	
Wolfensberger	 (2017)	 compared	 the	 effects	 of	 medetomidine	 and	
dexmedetomidine	 in	 60	 adults,	 healthy,	 isoflurane-	anaesthetized,	
client-	owned	horses	in	a	blinded,	randomized	study.	For	sedation	be-
fore	induction	of	general	anaesthesia,	18	of	30	horses	receiving	dex-
medetomidine	required	extra	top-	ups,	to	fulfil	sedation	criteria	(Taylor,	
Coumbe,	Henson,	Scott,	&	Taylor,	2014),	compared	to	two	of	the	30	
horses	receiving	medetomidine.	Median	total	sedation	doses	 (range)	
were	dexmedetomidine	4	μg/kg	(4–9)	or	medetomidine	7	μg/kg	(7–9).	
Cardiopulmonary	function	and	influences	in	FE′ISO	after	a	subjective	
control	of	anaesthetic	depth	did	not	differ	between	treatments.	After	
similar	anaesthesia	durations	 (approximate	mean	of	150	min),	recov-
eries	were	significantly	better	 in	horses	receiving	dexmedetomidine,	
with	no	differences	in	recovery	times.
A	 similar	 protocol	 has	 been	 used	 with	 success	 in	 five	 adults,	
client-	owned	 horses	with	 atrial	 fibrillation	 (AF)	 undergoing	 transve-
nous	 electrical	 cardioversion	 (TVEC)	 (Marly-	Voquer,	 Schwarzwald,	
&	 Bettschart-	Wolfensberger,	 2016).	 The	 horses	 were	 sedated	 with	
3.5	μg/kg	 dexmedetomidine,	 in	 two	 parts,	 1.75	μg/kg	 together	
with	30	μg/kg	butorphanol	 i.v.	 slowly	 in	 the	box,	and	 the	 remaining	
1.75 μg/kg	in	the	induction	room.	After	induction,	general	anaesthe-
sia	was	maintained	with	isoflurane	and	dexmedetomidine,	at	an	initial	
rate	of	1.75	μg	kg−1	hr−1,	adjusted	 later	to	the	horses′	requirements.	
For	sedation,	the	dose	of	3.5	μg/kg	was	only	sufficient	in	two	of	the	
five	horses	 [median	 total	 sedation	dose	 (range)	was	4.5	μg/kg	 (3.5–
10)].	For	maintenance,	only	one	horse	was	maintained	with	a	rate	of	
1.75 μg	kg−1	hr−1	 (median	 total	 infusion	 rate	 [range]	 2.3	μg	kg−1	hr−1 
[1.75–5.3]).	 Good	 recovery	 qualities	were	 observed	 after	 a	 1	μg/kg	
dexmedetomidine	bolus	(one	horse	received	3	μg/kg	as	it	had	exhib-
ited	 difficult	 behaviour	 before	 anaesthesia).	 In	 that	 case	 series,	 the	
authors	suggested	that	dexmedetomidine	may	have	beneficial	effects	
(cardioprotection	and	energy	sparing	effects	on	the	myocardium)	for	
these	procedures,	as	electric	 shocks	applied	directly	 to	 the	myocar-
dium	may	cause	a	degree	of	ischaemia.	They	concluded	that	the	myo-
cardial	damage	in	those	patients	was	“likely	minimal”	as	concentrations	
of	cardiac	troponin	I	were	only	“mildly	elevated”	in	one	horse	after	6	
and	in	another	for	24	hr.
The	 influence	 of	 these	 protocols	 on	 regional	 perfusion	 has	 also	
been	studied.	Neudeck,	Hopster,	and	Kästner	 (2016)	reported	a	de-
terioration	 of	 the	 oral,	 oesophageal	 and	 rectal	 blood	 flow	 and	 oxy-
genation	after	a	3.5	μg/kg	dexmedetomidine	bolus	in	six	experimental	
horses.	When	anaesthesia	was	maintained	with	desflurane	or	propo-
fol	 in	combination	with	dexmedetomidine	(7	μg	kg−1	hr−1),	peripheral	
tissue	 was	 well	 oxygenated,	 whereas	 microperfusion	 remained	 sig-
nificantly	 reduced.	 The	 maintenance	with	 propofol	 provided	 better	
pulmonary	perfusion	with	better	oxygenation	with	PaO2	values	 sig-
nificantly	higher	compared	with	desflurane,	with	dead	space	and	the	
alveolar-	arterial	gradient	significantly	lower.	Cardiac	index	was	signifi-
cantly	 higher	with	 desflurane,	whereas	 SVR	was	 significantly	 lower.	
The	 LiDCO	 technique	 was	 used	 to	 measure	 CO.	 In	 15	 isoflurane-	
anaesthetized	horses,	the	same	group	of	investigators	studied	the	ef-
fects	of	a	dexmedetomidine	infusion	(3.5	μg/kg	bolus	+	7	μg	kg−1	hr−1)	
on	 the	 peripheral	 gastrointestinal	 α2-	adrenoreceptors	 when	 given	
alone,	 and	 in	 combination	 with	 the	 peripheral	 antagonist	 MK-	467	
(Wittenberg-	Voges,	Hopster,	Raekallio,	Kästner,	&	Vainio,	2016).	The	
antagonist,	given	as	an	i.v.	bolus	(250	μg/kg)	after	2	hr	of	general	an-
aesthesia,	reversed	the	vasoconstriction	induced	by	the	dexmedeto-
midine,	resulting	in	a	drop	in	MAP	despite	increasing	CO.	Therefore,	
gastrointestinal	 microperfusion	 decreased,	 probably	 as	 a	 result	 of	
insufficient	perfusion	pressure.	The	authors	concluded	 that	an	 ideal	
agonist/antagonist	ratio,	and	an	infusion	rate	for	MK-	467,	was	still	to	
be	determined.	For	this	study,	CO	was	obtained	by	the	thermodilution	
technique.
4.3 | Minimum alveolar concentration no movement 
(MACNM) studies (2)
Two	experimental	MACNM	studies	with	 six	and	 five	ponies,	 respec-
tively,	 have	 been	 published	 using	 dexmedetomidine	CRIs	 using	 the	
same	 methodology.	 The	 sevoflurane	 MACNM	 value	 was	 reported	
to	 be	 2.42%	±	0.55%	 in	 Gozalo-	Marcilla,	 Hopster	 et	al.	 (2013).	 In	
the	 same	 experiment,	 dexmedetomidine	 3.5	μg/kg	 followed	 by	 a	
1.75 μg	kg−1	hr−1	 CRI	 significantly	 reduced	 the	 MACNM	 of	 sevoflu-
rane	 by	 53%	±	15%,	 down	 to	 1.07%	±	0.21%.	After	 an	 i.v.	 bolus	 of	
0.15	mg/kg,	 a	 morphine	 CRI	 (0.1	mg	kg−1	hr−1)	 increased	 the	 sevo-
flurane	MACNM	up	to	2.79%	±	0.73%.	However,	when	the	morphine	
CRI	was	co-	administered	with	a	dexmedetomidine	CRI,	 the	MACNM 
value	was	reduced	by	67%	±	11%,	down	to	0.89%	±	0.22%	(Gozalo-	
Marcilla,	Hopster	et	al.,	2014).
4.4 | TIVA studies (3)
In	 an	 experimental,	 nonblinded,	 randomized,	 cross-	over	 study,	
Hopster	et	al.	(2014)	reported	a	TIVA	protocol	for	120	min	with	dex-
medetomidine,	comparable	with	a	xylazine-	based	one,	with	mild-	to-	
moderate	 cardiovascular	 depression	 in	 eight	 adults,	 healthy	 horses.	
This	consisted	of	a	3.5	μg/kg	sedation	dose,	followed	by	dexmedeto-
midine	 (7	μg	kg−1	hr−1),	 midazolam	 (0.1	mg	kg−1	hr−1)	 and	 ketamine	
(3	mg	kg−1	hr−1)	 infusions.	 To	 determine	 an	 adequate	 anaesthetic	
depth,	a	constant,	electrical	current	was	applied	at	regular	 intervals.	
Good	to	excellent	 recoveries	were	observed	after	 reversal	of	mida-
zolam	with	flumazenil.	Cardiac	output	was	measured	by	transthoracic	
echocardiography.	Under	 these	circumstances,	mean	dexmedetomi-
dine	half-	life	(±SD)	was	46	±	7	min,	shorter	than	the	one	of	xylazine	
(64	±	13	min).
Dexmedetomidine	(1.5	μg	kg−1	hr−1),	ketamine	(1	mg	kg−1	hr−1)	
and	 propofol	 (8	mg	kg−1	hr−1)	 CRIs	 after	 sedation	 with	 twice	
0.5	mg/kg	 i.v.	 xylazine	 (first	 dosage	 to	 allow	 thermodilution	
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catheter	 insertion	 for	 CO	measurement)	 and	 induction	with	 ket-
amine	 (2	mg/kg)	 and	 propofol	 (0.4	mg/kg)	 were	 compared	 with	
a	 PIVA	 regime,	 replacing	 the	 propofol	 CRI	 by	 isoflurane	mainte-
nance.	This	TIVA	 protocol	 provided	 adequate	 surgical	 conditions	
in	 six	 adults,	 healthy	 horses	 undergoing	 arthroscopy	 for	 periods	
around	 60–90	min	 in	 an	 experimental,	 nonblinded,	 randomized,	
cross-	over	 study	 (Duke-	Novakovski	 et	al.,	 2015).	 However,	 at	
comparable	 mean	 FiO2	 values	 ranging	 from	 77%	 and	 94%,	 the	
TIVA	protocol	 lowered	PaO2	values	 for	 the	study	period	 (255	vs.	
380	mmHg	for	TIVA	and	PIVA	at	60	min,	respectively).	The	authors	
recommended	the	use	of	oxygen	and	the	availability	of	mechanical	
lung	ventilation	with	propofol-	based	TIVA	techniques.	The	experi-
mental	study	of	Neudeck	et	al.	(2016)	compared	regional	perfusion	
between	a	PIVA	with	desflurane	and	TIVA	with	propofol.	After	se-
dation	with	dexmedetomidine	(3.5	μg/kg)	and	induction	with	ket-
amine	(1	mg/kg)	and	propofol	(2	mg/kg),	maintenance	consisted	of	
a 7 μg	kg−1	hr−1	dexmedetomidine	CRI	with	an	infusion	of	propofol,	
with	 a	 minimum	 infusion	 rate	 (MIR)	 of	 0.04	±	0.01	mg	kg−1	hr−1. 
With	 both	 protocols,	 peripheral	 tissue	 was	 well	 oxygenated,	
whereas	microperfusion	was	 reduced.	However,	 the	TIVA	 proto-
col	provided	better	pulmonary	perfusion	and	oxygenation.	Cardiac	
index,	measured	by	LiDCO,	was	better	preserved	with	desflurane,	
whereas	SVR	was	lower.
4.5 | Other studies (2)
In	six	healthy	horses	anaesthetized	for	1	hr	with	sevoflurane,	the	re-
covery	qualities	did	not	differ	after	small	i.v.	boli	of	xylazine	(0.2	mg/
kg)	versus	dexmedetomidine	(0.875	μg/kg).	Although	not	significant,	
the	VAS	scores	to	grade	recovery	quality	 (0	poor	recovery,	100	ex-
cellent)	were	71	±	21	for	xylazine	and	84	±	13	for	dexmedetomidine	
(Guedes,	Tearney,	Cenani,	Aristizabal,	&	Nieto,	2017).
One	in	vitro	study	of	Ambrisko,	Kabes,	and	Moens	(2013)	evalu-
ated	the	effects	of	different	drugs	on	the	voltage	of	the	sensor	used	
for	 the	 LiDCO	method	 to	measure	CO,	which	 is	 commonly	 used	 in	
equine	studies.	Dexmedetomidine	was	classified	as	a	drug	that	may	
interact	with	the	sensor	but	 is	unlikely	to	cause	bias	 in	LiDCO	mea-
surements	in	vivo.
5  | DISCUSSION
High-	quality	 research	 has	 been	 performed	 in	 the	 last	 decade	 with	
respect	to	the	use	of	dexmedetomidine	in	the	equine.	Based	on	the	
evidence	reported	by	the	studies	reviewed	here,	it	can	be	stated	that	
dexmedetomidine	 is	 an	 attractive	 drug	 to	 be	 used	 in	 horses.	 Its	 ki-
netics	favour	the	use	of	this	drug	for	sedation	in	prolonged	standing	
procedures	and	during	PIVA	and	TIVA.	However,	 in	some	countries	
depending	 on	 national	 legislation,	 scientific	 evidence	 showing	 clear	
advantages	compared	to	licensed	drugs	should	be	provided	to	support	
its	 off-	label	 use	 (e.g.,	 in	EU	 countries).	Unfortunately,	 the	 literature	
comparing	dexmedetomidine	with	other	α2-	agonists	 is	 scarce	and	a	
direct	comparison	between	them	is	difficult.
Bettschart-	Wolfensberger	et	al.	 (2005)	 reported	 the	PK	and	car-
diopulmonary	effects	of	a	3.5	μg/kg	i.v.	dexmedetomidine	bolus,	with	
promising	results.	The	authors	concluded	that	this	drug	might	be	safe	
for	sedation,	with	similar	cardiopulmonary	changes	to	those	produced	
by	other	α2-	agonists,	but	of	very	short	duration.	Furthermore,	its	PK	
profile	characterized	by	a	short	half-	life	and	rapid	redistribution	might	
be	useful	in	infusions,	for	long-	term	sedation	and	in	combination	with	
other	general	anaesthetics	in	PIVA	and	TIVA	protocols.	It	was	after	its	
license	in	the	EU	in	2007	for	dogs	and	cats	that	more	studies	began	to	
be	designed	in	the	equine.
When	comparing	the	different	PK	studies	of	dexmedetomidine,	it	
is	difficult	to	draw	a	conclusion,	mainly	due	to	the	different	method-
ologies	used,	and	also	 the	absence	of	articles	directly	comparing	 its	
effects	with	those	of	other	α2-	agonists.	Most	authors	used	noncom-
partmental	analysis	 (Bettschart-	Wolfensberger	et	al.,	2005;	Ranheim	
et	al.,	2015;	Rezende	et	al.,	2015).	The	most	 interesting	 finding	was	
the	rapid	drug	elimination.	Mean	(±SD)	half-	lives	of	dexmedetomidine	
following	 an	 i.v.	 bolus	 in	 young	 and	 adult	 ponies	were	 19.8	±	9.63	
and	 28.96	±	7.61	min,	 respectively,	 (Bettschart-	Wolfensberger	 et	al.,	
2005)	 and	 in	 horses	 was	 shorter,	 8.03	±	0.84	min	 (Rezende	 et	al.,	
2015).	After	CRI	 termination,	 Ranheim	 et	al.	 (2015)	 reported	 a	 har-
monic	mean	(pseudo-	SD)	value	of	20.3	(5.8)	min.	In	horses	anaesthe-
tized	with	a	dexmedetomidine-	based	TIVA	protocol,	the	mean	half-	life	
(±SD)	was	slightly	longer	(46	±	7	min)	but	shorter	than	that	of	xylazine	
(64	±	13	min)	(Hopster	et	al.,	2014),	also	with	higher	plasma	concen-
trations,	probably	due	to	the	reduced	CO	by	the	co-	administration	of	
other	sedatives	and	anaesthetics.
Only	the	study	of	Grimsrud	et	al.	(2015)	compared	the	PK	of	dex-
medetomidine	with	those	of	medetomidine	and	detomidine.	Although	
in	 the	 authors′	 experience,	 the	doses	of	 detomidine	were	 relatively	
high	compared	to	those	of	the	other	drugs,	dexmedetomidine	was	the	
drug	with	higher	CL	and	less	V1	and	V2.	Extrapolating	from	other	stud-
ies,	elimination	half-	times	are	shorter	than	those	of	the	racemate	me-
detomidine;	mean	(±SD)	half-	lives	were	reported	of	51.3	±	13.1	min	in	
ponies	(Bettschart-	Wolfensberger,	Clarke,	Vainio,	Aliabadi,	&	Demuth,	
1999)	and	29.1	±	12.5	in	horses	(Grimsrud,	Mama,	Steffey,	&	Stanley,	
2012).	In	a	noncompartmental	model,	the	median	half-	life	of	detomi-
dine	in	horses	was	24.06	(range	12.68–41.26)	min	(Grimsrud,	Mama,	
Thomasy,	&	Stanley,	2009).	With	a	two-	compartment	model,	median	
elimination	half-	life	of	romifidine	in	horses	was	138.2	(range	104.6–
171.0)	min	 (Wojtasiak-	Wypart	et	al.,	2012).	 In	a	 three-	compartment	
model,	beta	and	gamma	half-	lives	for	xylazine	were	167.4	±	6.3	and	
1560	±	114	min,	 respectively	 (Knych,	 Stanley,	 McKemie,	 Arthur,	 &	
Kass,	2017).
The	higher	α2:α1	adrenoreceptor	sensitivity	(ratio	of	1620:1),	com-
pared	to	xylazine	(160:1),	detomidine	(260:1)	and	romifidine	(340:1),	
may	lead	to	less	adverse	effects.	In	their	PK/PD	modelling	study	com-
paring	the	PK	effects	of	detomidine,	medetomidine	and	dexmedeto-
midine,	and	their	PD	responses,	Grimsrud	et	al.	(2015)	explained	the	
higher	reductions	in	HR	and	HHAG	with	detomidine	through	its	lower	
α2:α1	ratio.	Moreover,	dexmedetomidine	would	be	preferable	in	those	
cases	in	which	an	increase	in	plasma	glucose	concentrations	is	not	de-
sired,	such	as	in	horses	with	insulin	resistance.
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Therefore,	 based	 on	 its	 PK	 profile,	 dexmedetomidine	 may	 be	
useful	 for	 both	 short-	 and	 long-	term	 standing	 procedures.	 Rates	 of	
7 μg	kg−1	hr−1	 after	 a	 bolus	 of	 3.5	μg/kg	 were	 proven	 to	 be	 equi-
sedative	 to	 a	 sedation	 dose	 of	 xylazine	 at	 0.5	mg/kg	 followed	 by	 a	
1	mg	kg−1	hr−1	CRI	(Müller	et	al.,	2012).	Antinociception	was	present	
at	rates	of	4	and	6	μg	kg−1	hr−1	(Risberg	et	al.,	2014).	However,	under	
clinical	circumstances,	the	veterinarian	should	be	ready	to	adapt	the	
theoretical	rates	to	each	patient,	due	to	individual	variations	in	plasma	
concentrations	 (Ranheim	 et	al.,	 2015;	 Risberg	 et	al.,	 2014).	 Indeed,	
steady	sedation	was	not	reached	when	using	5	μg	kg−1	hr−1	alone,	or	
3.5	μg	kg−1	hr−1	combined	with	butorphanol	(Medeiros	et	al.,	2017).
When	used	during	general	anaesthesia	as	a	CRI,	as	part	of	PIVA	
protocols,	dexmedetomidine	fulfils	the	principles	of	equine	“balanced	
anaesthesia,”	 which	 include	 mainly	 three	 requirements:	 (i)	 an	 ade-
quate	 intraoperative	 cardiopulmonary	 function,	 (ii)	 reduction	 in	 the	
inhalant	agent	requirements	and	(iii)	smooth	and	coordinated	recov-
eries	 (Bettschart-	Wolfensberger	 &	 Larenza,	 2007;	 Gozalo-	Marcilla,	
Gasthuys,	&	Schauvliege,	2014,	2015).
First,	 in	 their	 experimental	 study,	Marcilla	 et	al.	 (2010)	 reported	
clinically	 acceptable	 cardiopulmonary	 effects	 observed	 in	 healthy	
ponies	 at	 both	 rates	 studied,	 1	 and	1.75	μg	kg−1	hr−1.	However,	 the	
design	 of	 that	 study	 comprised	 one	 important	 limitation.	 Potential	
carry-	over	 effects	 of	 the	 CRI	 infused	 during	 the	 first	 period	 may	
have	influenced	the	cardiopulmonary	effects	of	the	second	period.	A	
blinded,	randomized,	cross-	over	study	with	three	treatments,	a	saline	
and	the	two	dexmedetomidine	CRIs,	would	have	been	more	appropri-
ate.	Under	general	 anaesthesia,	 the	 limited	 cardiopulmonary	effects	
of	 dexmedetomidine	CRIs	 ranging	 from	1	 to	 1.75	μg	kg−1	hr−1 were 
confirmed	in	both	experimental	(Benmansour	et	al.,	2014)	and	clinical	
studies	(Marcilla	et	al.,	2012).	Whereas	the	low	dose	was	used	in	com-
bination	with	different	opioid	infusions	(Benmansour	et	al.,	2014),	the	
use	of	the	higher	rate	was	justified	by	its	theoretically	higher	sedative,	
analgesic	and	inhalant	sparing	effects	(Marcilla	et	al.,	2012).	Neudeck	
et	al.	(2016)	demonstrated	that	dexmedetomidine	causes	a	decrease	
in	 regional	blood	 flow,	but	 further	studies	are	needed	to	assess	 the	
clinical	importance	of	these	changes.	It	is	also	very	important	to	note	
that	all	the	studies	involved	healthy	horses.	While	it	may	be	discussed	
whether	 or	 not	 the	 reductions	 in	 cardiopulmonary	 function	 in	 the	
study	 of	 Risberg	 et	al.	 (2016)	 are	 of	 clinical	 importance	 in	 healthy	
horses,	these	changes	may	be	of	huge	importance	in	colic	horses.
Second,	a	dexmedetomidine	CRI	halved	the	sevoflurane	MACNM 
values	under	experimental	conditions	(Gozalo-	Marcilla,	Hopster	et	al.,	
2013).	The	same	study	design	reported	an	increase	in	MACNM value 
when	morphine	was	 infused	 alone,	 and	 its	 further	 reduction	when	
both	CRIs	are	co-	administered	(Gozalo-	Marcilla,	Hopster	et	al.,	2014).	
There	is	only	one	study	with	similar	methodology	in	α2-	agonists	report-
ing	a	reduction	of	28%	in	the	desflurane	requirements	when	infusing	
a	 medetomidine	 CRI	 (Bettschart-	Wolfensberger,	 Jäggin-	Schmucker,	
Lendl,	 Bettschart,	 &	 Clarke,	 2001).	 Experimental	 studies	 describing	
these	 effects	 of	 infusions	 of	 xylazine,	 detomidine	 and	 romifidine	 in	
the	equine	are	missing.	Blinded	clinical	studies	appear	not	to	be	good	
options	to	detect	reductions	in	inhalants,	especially	when	depth	of	an-
aesthesia	is	evaluated	subjectively,	according	to	clinical	signs.	This	is	of	
extreme	importance	in	horses	with	infusions	of	α2-	agonists,	in	which	
a	“lighter”	appearance,	compared	with	traditional	inhalant	protocols,	is	
common	(Kalchofner	et	al.,	2006).	No	isoflurane	concentration	reduc-
tions	 were	 demonstrated	 after	 romifidine	 (Devisscher,	 Schauvliege,	
Dewulf,	&	Gasthuys,	2010),	detomidine	(Schauvliege	et	al.,	2011)	and	
dexmedetomidine	 (Marcilla	 et	al.,	 2012).	The	 same	happened	 in	 the	
comparison	 between	 medetomidine	 and	 dexmedetomidine	 (Sacks	
et	al.,	2017).	This	may	be	solved	using	objective	methods,	such	as	the	
flow	chart	described	by	Enderle	et	al.	(2008).	With	this	tool,	Gozalo-	
Marcilla,	Steblaj	et	al.	(2013)	showed	that	with	initial	FE′ISO	values	of	
0.9%,	a	dexmedetomidine	CRI	maintained	a	more	stable	surgical	an-
aesthetic	depth,	with	fewer	ketamine	“top-	ups”	and	lower	isoflurane	
requirements	 compared	 with	 a	 morphine	 infusion.	 The	 isoflurane-	
sparing	effects	of	a	xylazine	CRI	in	a	clinical	study	were	demonstrated,	
using	a	“more	or	less	objective”	scoring	system,	based	on	clinical	signs	
and	MAP.	However,	these	results	have	to	be	interpreted	carefully	as	
the	main	anaesthetist	was	aware	of	the	drugs	administered	(Pöppel,	
Hopster,	Geburek,	&	Kästner,	2015).
Finally,	 as	 the	 third	 requirement	 for	 PIVA	 protocols,	 recovery	
qualities	 after	 dexmedetomidine	 infusions	 are	 from	 good	 to	 excel-
lent,	with	no	apparent	signs	of	excitement	(Benmansour	et	al.,	2014;	
Marly-	Voquer	et	al.,	2016;	Risberg	et	al.,	2016).	After	a	CRI	of	dexme-
detomidine	during	 isoflurane	anaesthesia,	 followed	by	a	 small	bolus	
for	recovery,	the	recoveries	were	better	than	after	infusions	of	saline	
(Marcilla	 et	al.,	 2012),	 medetomidine	 (Sacks	 et	al.,	 2017)	 and	 mor-
phine	(Gozalo-	Marcilla,	Steblaj	et	al.,	2013).	After	a	dexmedetomidine	
infusion,	small	doses	of	 romifidine	have	been	administered	by	other	
authors	 (Benmansour	 &	 Duke-	Novakovski,	 2013;	 Duke-	Novakovski	
et	al.,	 2015),	 probably	 due	 to	 personal	 preferences.	 Small	 doses	 of	
xylazine,	 detomidine	 and	 romifidine	 are	well	 known	 to	 improve	 the	
quality	of	recovery	in	horses	after	inhalant	anaesthesia	(Santos	et	al.,	
2003),	with	 no	differences	 between	 xylazine	 and	dexmedetomidine	
(Guedes	et	al.,	2017).	However,	as	the	study	of	Guedes	et	al.	 (2017)	
included	only	six	horses,	further	studies	with	more	individuals	are	re-
quired	to	confirm	that	 there	are	not	real	differences	between	those	
α2-	agonists.
The	clinical	applicability	of	these	protocols	was	confirmed	under	
different	circumstances,	for	medium	term	(Gozalo-Marcilla,	Steblaj	et	al.,	
2013;	Marcilla	et	al.,	2012;	Sacks	et	al.,	2017)	and	prolonged	anaes-
thesias	 (Benmansour	&	Duke-	Novakovski,	 2013).	 Its	 use	 in	 the	 last	
case	 is	 justified	by	 the	 favourable	kinetics.	Moreover,	Marly-	Voquer	
et	al.	 (2016)	suggested	that,	 in	horses	with	AF	for	TVEC,	 the	use	of	
an	intraoperative	infusion	of	dexmedetomidine	may	be	of	benefit	due	
to	the	cardioprotective	properties	of	this	drug,	based	on	the	minimal	
changes	in	the	concentrations	of	cardiac	troponin	I.	However,	cardiac	
troponin	I	values	were	also	normal	after	3	hr	after	TVEC	in	six	horses	
sedated	with	detomidine	prior	general	anaesthesia	 (De	Clercq	et	al.,	
2008).	Further	research	is	required	to	confirm	whether	this	drug	may	
have	any	benefit	from	other	α2-	agonists.
Dexmedetomidine	can	also	be	used	in	TIVA	protocols	which	nor-
mally include an α2-	agonist,	a	centrally	acting	muscle	relaxant	and	an	
i.v.	 anaesthetic	agent,	mostly	ketamine	 (Hopster	et	al.,	2014).	These	
regimes	 produce	 general	 anaesthesia,	 avoid	 the	 cardiopulmonary	
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effects	 of	 inhalant	 anaesthetics	 and	 reduce	 mortality	 but	 must	 be	
limited	 to	 surgical	 procedures	 of	 less	 than	 60–90	min	 (Johnston,	
Eastment,	Wood,	 &	 Taylor,	 2002).	 The	 use	 of	 dexmedetomidine	 is	
attractive	 in	 these	 cases,	 as	 recovery	 times,	 though	 not	 statistically	
different,	were	shorter	compared	to	xylazine-	based	protocols,	mainly	
due	 to	 the	 longer	 elimination	 half-	time	 of	 xylazine	 (Hopster	 et	al.,	
2014).	Both	oxygen	supplementation	and	mechanical	ventilation	are	
recommended	when	propofol-	based	TIVA	protocols	are	used	(Duke-	
Novakovski	et	al.,	2015).
However,	 the	 use	 of	 dexmedetomidine	 is	mainly	 limited	 due	 to	
current	 legal	 requirements.	Worldwide,	 dexmedetomidine	 is	 not	 li-
censed	for	use	in	food-	producing	animals,	but	only	for	dogs	and	cats.	
For	example,	 in	 the	EU,	 the	cascade	system	does	not	allow	the	off-	
label	use	of	dexmedetomidine	in	food-	producing	horses,	and	a	reason	
for	its	preferential	use	over	other	sedatives	is	mandatory	in	nonfood-	
producing	horses.	Moreover,	in	countries	where	this	drug	is	licensed	
for	veterinary	use,	 its	elevated	costs	make	 its	use	for	private	practi-
tioners	and/or	practices	limited.
A	 common	 complaint	 from	 anaesthetists	 and	 practitioners	 is	
that	dexmedetomidine	does	not	provide	a	 reliable	 level	of	sedation.	
Assuming	 preliminary	 results	 from	 their	 laboratory,	 3.5	μg/kg	 was	
shown	 to	be	 the	 equisedative	 to	1	mg/kg	of	 xylazine	or	7	μg/kg	of	
medetomidine	(Bettschart-	Wolfensberger	et	al.,	2005).	However,	clin-
ically	the	proposed	dose	of	3.5	μg/kg	does	not	seem	to	provide	a	reli-
able	level	of	sedation,	and	incremental	dosing	is	frequently	needed	to	
obtain	adequate	 sedation	 levels	 (Marcilla	et	al.,	 2012;	Marly-	Voquer	
et	al.,	2016;	Sacks	et	al.,	2017).
A	 possible	 criticism	 to	 some	 of	 the	 studies	 presented	 in	 this	
review	 is	 that	 the	LiDCO	was	used	 for	CO	measurement	 (Gozalo-
Marcilla,	 Steblaj	 et	 al.,	 2013;	Marcilla	 et	al.,	 2012;	Neudeck	 et	al.,	
2016;	 Risberg	 et	al.,	 2016).	 This	 method	 to	 evaluate	 the	 cardio-
pulmonary	function	 is	nowadays	of	huge	value	 in	research,	mainly	
under	 clinical	 circumstances,	 due	 to	 minimal	 invasiveness.	 The	 in	
vitro	 study	 of	Ambrisko	 et	al.	 (2013)	 confirms	 that	 dexmedetomi-
dine	is	a	drug	that	may	interact	with	the	sensor	but	unlikely	to	cause	
bias	 in	 LiDCO	 in	 vivo.	The	 use	 of	 other	 drugs,	 such	 as	 ketamine,	
may	have	caused	a	more	influencing	bias	due	to	interaction	with	the	
sensor	in	studies	with	anaesthetized	horses.
6  | CONCLUSION
The	evidence	provided	by	the	studies	reviewed	here	supports	the	use	
of	dexmedetomidine	in	the	horse.	Dexmedetomidine’s	PK	profile	fa-
vours	 its	clinical	application,	mainly	for	standing	sedation,	PIVA	and	
TIVA	procedures.	However,	due	to	strict	legislation	requirements,	fur-
ther	research	is	needed	(mainly	directly	comparing	dexmedetomidine	
to	other	α2-	agonists)	to	allow	its	off-	label	use	in	countries	under	EU	
regulations.
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A P P E N D I X   1 Levels	of	evidence	are	categorized	and	reported	
adapted	from	Howick	et	al.	(2011)
Level of evidence Description
I Evidence	obtained	from	a	systematic	review	
of	all	relevant	controlled	trials
II Evidence	obtained	from	at	least	one	properly	
designed,	randomized	controlled	trial
III-	1 Evidence	obtained	from	well-	designed,	
pseudorandomized	controlled	trials	
(alternate	allocation	or	some	other	method)
III-	2 Evidence	obtained	from	comparative	studies	
with	concurrent	controls	and	allocation	not	
randomized	(cohort	studies),	case–control	
studies	or	interrupted	time	series	with	a	
control	group
III-	3 Evidence	obtained	from	comparative	studies	
with	historical	controls,	two	or	more	
single-	arm	studies,	or	interrupted	time	
series	without	a	parallel	control	group
IV Evidence	obtained	from	case	series,	either	
post-	test	or	pretest	and	post-	test
V Expert	opinion	without	explicit	critical	
appraisal,	or	based	on	physiology,	bench	
research	or	“first	principles”
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